PATENT CLAIM ANALYSIS

Application Number: 15513112
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-09
Patent Classification: ["514", "262100"]

Abstract:
Disclosed are methods for treating autism spectrum disorders and/or anxiety disorders by administering certain NR2B subunit-selective NMDA (N methyl-D aspartate) antagonists. Anxiety disorders include agoraphobia (with or without panic disorder), generalized anxiety disorder (GAD), social anxiety disorder (SAD), panic disorder (PD), post-traumatic stress disorder (PTSD) and obsessive-compulsive disorder (OCD).

Claim (Index 23):
A method for treating an autism spectrum disorder in an individual in need thereof comprising administering to the individual an effective amount of an NR2B subunit-selective NMDA antagonist, wherein the antagonist is (+)-(1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenyl-piperidino)-1-propanol, cis-4-methylbenzyl 3-fluoro-4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, or N-(1-(2,2-difluoro-2-(4-trifluoromethyl)phenyl-ethyl)piperidin-4-yl)-1H-pyrazolo-[3,4-d]pyrimidin-4-amine, or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 52.0
- Percentile: 96.0
- Lexical Diversity: 1.60465
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15538015', '09969317', '11933056', '16046332', '11535455']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7660205977520643
- 35 USC 102 Novelty (BERT): 0.5163055906023012
- Combined Prediction Score: 0.741049097037088
- Mean Citation Score: 285.661044
- Max Citation Score: 318.88898
- Similarity Product: 252.93565433554053

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test